| Homereach Llc | |
| 8000 S Us 1 Ste 200, Port Saint Lucie, Florida 34952 | |
| (772) 878-3534 | |
| Name | Homereach Llc |
|---|---|
| Location | 8000 S Us 1 Ste 200, Port Saint Lucie, Florida |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 109799 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 32958, 32960, 32968, 33455, 34946, 34947, 34949, 34950, 34951, 34952, 34953, 34956, 34957, 34981, 34982, 34983, 34984, 34986, 34990, 34994, 34996, 34997 |
| NPI Number | 1013296227 |
| Organization Name | HOMEREACH, LLC |
| Address | 8000 S Us Hwy 1, Suite 200, Port St Lucie, FL 34952 |
| Phone Number | 772-878-3534 |
News Archive
The Society for Women's Health Research (SWHR®), the leading voice on the study of the biological differences between women and men, is co-sponsoring the National Institutes of Health (NIH) Forum on the Microbiome and Autoimmunity on Thursday, April 24, at the NIH in Bethesda, Md.
UT Southwestern Medical Center research supports an evidence-based medicine approach that embraces individualized care to prevent overtreatment, specifically for patients with type 2 diabetes.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.
Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer's disease. Neuronetrix will be utilizing their COGNISION System to measure and analyze cognitive biomarkers in study participants.
Kidney dialysis treatment in the U.S. is costly and has high death rates, but it doesn't have to be that way, USA Today reports: "The vast majority of the more than 350,000 Americans on dialysis are treated in centers, where three treatments a week, three or four hours each, is the norm — not because it's optimal but because that's the way it has been done for nearly four decades.
› Verified 8 days ago
| Quality Rating: |
News Archive
The Society for Women's Health Research (SWHR®), the leading voice on the study of the biological differences between women and men, is co-sponsoring the National Institutes of Health (NIH) Forum on the Microbiome and Autoimmunity on Thursday, April 24, at the NIH in Bethesda, Md.
UT Southwestern Medical Center research supports an evidence-based medicine approach that embraces individualized care to prevent overtreatment, specifically for patients with type 2 diabetes.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.
Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer's disease. Neuronetrix will be utilizing their COGNISION System to measure and analyze cognitive biomarkers in study participants.
Kidney dialysis treatment in the U.S. is costly and has high death rates, but it doesn't have to be that way, USA Today reports: "The vast majority of the more than 350,000 Americans on dialysis are treated in centers, where three treatments a week, three or four hours each, is the norm — not because it's optimal but because that's the way it has been done for nearly four decades.
› Verified 8 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 85.7 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99.2 | 98.6 |
| How often the home health team checked patients’ risk of falling | 95.2 | 99.6 |
| How often the home health team checked patients for depression | 85.7 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 20 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 25.6 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 91.7 | 96.4 |
News Archive
The Society for Women's Health Research (SWHR®), the leading voice on the study of the biological differences between women and men, is co-sponsoring the National Institutes of Health (NIH) Forum on the Microbiome and Autoimmunity on Thursday, April 24, at the NIH in Bethesda, Md.
UT Southwestern Medical Center research supports an evidence-based medicine approach that embraces individualized care to prevent overtreatment, specifically for patients with type 2 diabetes.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.
Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer's disease. Neuronetrix will be utilizing their COGNISION System to measure and analyze cognitive biomarkers in study participants.
Kidney dialysis treatment in the U.S. is costly and has high death rates, but it doesn't have to be that way, USA Today reports: "The vast majority of the more than 350,000 Americans on dialysis are treated in centers, where three treatments a week, three or four hours each, is the norm — not because it's optimal but because that's the way it has been done for nearly four decades.
› Verified 8 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 78.8 | 79.6 |
| How often patients got better at getting in and out of bed | 69.5 | 81.1 |
| How often patients got better at bathing | 83.8 | 82.3 |
| How often patients’ breathing improved | 97.5 | 82.8 |
| How often patients’ wounds improved or healed after an operation | - | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 65.1 | 75 |
| How often home health patients had to be admitted to the hospital | 12.1 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 18.9 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 97.5 | 94 |
News Archive
The Society for Women's Health Research (SWHR®), the leading voice on the study of the biological differences between women and men, is co-sponsoring the National Institutes of Health (NIH) Forum on the Microbiome and Autoimmunity on Thursday, April 24, at the NIH in Bethesda, Md.
UT Southwestern Medical Center research supports an evidence-based medicine approach that embraces individualized care to prevent overtreatment, specifically for patients with type 2 diabetes.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.
Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer's disease. Neuronetrix will be utilizing their COGNISION System to measure and analyze cognitive biomarkers in study participants.
Kidney dialysis treatment in the U.S. is costly and has high death rates, but it doesn't have to be that way, USA Today reports: "The vast majority of the more than 350,000 Americans on dialysis are treated in centers, where three treatments a week, three or four hours each, is the norm — not because it's optimal but because that's the way it has been done for nearly four decades.
› Verified 8 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
The Society for Women's Health Research (SWHR®), the leading voice on the study of the biological differences between women and men, is co-sponsoring the National Institutes of Health (NIH) Forum on the Microbiome and Autoimmunity on Thursday, April 24, at the NIH in Bethesda, Md.
UT Southwestern Medical Center research supports an evidence-based medicine approach that embraces individualized care to prevent overtreatment, specifically for patients with type 2 diabetes.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.
Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer's disease. Neuronetrix will be utilizing their COGNISION System to measure and analyze cognitive biomarkers in study participants.
Kidney dialysis treatment in the U.S. is costly and has high death rates, but it doesn't have to be that way, USA Today reports: "The vast majority of the more than 350,000 Americans on dialysis are treated in centers, where three treatments a week, three or four hours each, is the norm — not because it's optimal but because that's the way it has been done for nearly four decades.
› Verified 8 days ago
The patient survey data of Homereach Llc is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 73 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 64 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 63 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 67 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 47 | 78 |
News Archive
The Society for Women's Health Research (SWHR®), the leading voice on the study of the biological differences between women and men, is co-sponsoring the National Institutes of Health (NIH) Forum on the Microbiome and Autoimmunity on Thursday, April 24, at the NIH in Bethesda, Md.
UT Southwestern Medical Center research supports an evidence-based medicine approach that embraces individualized care to prevent overtreatment, specifically for patients with type 2 diabetes.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.
Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer's disease. Neuronetrix will be utilizing their COGNISION System to measure and analyze cognitive biomarkers in study participants.
Kidney dialysis treatment in the U.S. is costly and has high death rates, but it doesn't have to be that way, USA Today reports: "The vast majority of the more than 350,000 Americans on dialysis are treated in centers, where three treatments a week, three or four hours each, is the norm — not because it's optimal but because that's the way it has been done for nearly four decades.
› Verified 8 days ago
Best Pcs Llc Location: 1617 Se Port St Lucie Blvd, Port Saint Lucie, Florida 34952 Ratings: Phone: (772) 344-6598 | |
Nurse On Call Location: 291 Nw Peacock Blvd Ste 201, Port Saint Lucie, Florida 34986 Ratings: Phone: (772) 337-6610 | |
Kindred At Home Location: 525 Nw Lake Whitney Pl Ste 106, Port Saint Lucie, Florida 34986 Ratings: Phone: (772) 335-3245 | |
Family Home Health Services Location: 1801 Se Hillmoor Dr Ste B-107a, Port Saint Lucie, Florida 34952 Ratings: Phone: (561) 855-4700 | |
Carter Healthcare Location: 1401 Se Goldtree Dr Ste 101, Port Saint Lucie, Florida 34952 Ratings: Phone: (772) 335-0166 | |
Mihom Healthcare, Inc. Location: 2100 Se Hillmoor Dr Ste 102, Port Saint Lucie, Florida 34952 Ratings: Phone: (772) 873-3838 |